PMID- 15707470
OWN - NLM
STAT- MEDLINE
DCOM- 20050408
LR  - 20131121
IS  - 1368-5031 (Print)
IS  - 1368-5031 (Linking)
VI  - 59
IP  - 1
DP  - 2005 Jan
TI  - Efficacy and tolerability of candesartan cilexetil vs. amlodipine as assessed by 
      home blood pressure in hypertensive patients.
PG  - 78-84
AB  - This randomised, double-blind study compared the anti-hypertensive efficacy and 
      tolerability of Candesartan cilexetil (CC 8-16 mg) and Amlodipine (AML 5-10 mg) 
      on home blood pressure (HBP) measurements in mild-to-moderate hypertensive 
      patients. After a 2-week wash-out, patients aged 18-74 years, with a sitting 
      diastolic blood pressure (sDBP)=95-115 mmHg, untreated or intolerant to therapy 
      or uncontrolled were randomised to CC 8 mg or AML 5 mg O.D. for 12 weeks (W12). 
      Patients not normalised or not responders at W12 had their dose doubled for the 
      remaining 6 weeks. HBP was measured before each visit, during 5 days (three 
      measurements in the morning, 24 h after last dose and before drug intake and 
      three measurements before bedtime). The primary criterion was the comparison of 
      mean morning sDBP at baseline and post-treatment. A total of 638 patients were 
      enrolled, 540 of whom were randomised to CC or AML. The intent-to-treat and 
      safety analyses were performed in 532 patients while 321 constituted the per 
      protocol population. Baseline characteristics and BP values of the two groups 
      were similar. Morning sDBP did not differ between groups at W12, but AML patients 
      had significantly more adverse events (AEs) than those treated by CC (28 vs. 20%, 
      p=0.03); 6% of AML patients vs. 1% of CC patients were withdrawn due to AEs 
      (p=0.009). CC demonstrates a better tolerability over AML and an equivalent 
      anti-hypertensive efficacy in terms of morning home DBP after 12 weeks of 
      treatment.
FAU - Imbs, J-L
AU  - Imbs JL
AD  - Service de Cardiologie, CHU, Strasbourg, Laboratoires TAKEDA, Puteaux, France. 
      jean-louis.imbs@pharmaco-ulp.u-strasbg.fr
FAU - Nisse-Durgeat, S
AU  - Nisse-Durgeat S
CN  - French Collaborative Candesartan Study Group
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - India
TA  - Int J Clin Pract
JT  - International journal of clinical practice
JID - 9712381
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Benzimidazoles)
RN  - 0 (Biphenyl Compounds)
RN  - 0 (Tetrazoles)
RN  - 1J444QC288 (Amlodipine)
RN  - R85M2X0D68 (candesartan cilexetil)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Amlodipine/adverse effects/*therapeutic use
MH  - Antihypertensive Agents/adverse effects/*therapeutic use
MH  - Benzimidazoles/adverse effects/*therapeutic use
MH  - Biphenyl Compounds/adverse effects/*therapeutic use
MH  - Blood Pressure Monitoring, Ambulatory/methods
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Hypertension/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Patient Compliance
MH  - Tetrazoles/adverse effects/*therapeutic use
MH  - Treatment Outcome
EDAT- 2005/02/15 09:00
MHDA- 2005/04/09 09:00
CRDT- 2005/02/15 09:00
PHST- 2005/02/15 09:00 [pubmed]
PHST- 2005/04/09 09:00 [medline]
PHST- 2005/02/15 09:00 [entrez]
AID - IJCP296 [pii]
AID - 10.1111/j.1742-1241.2005.00296.x [doi]
PST - ppublish
SO  - Int J Clin Pract. 2005 Jan;59(1):78-84. doi: 10.1111/j.1742-1241.2005.00296.x.